Logo

Pfizer and BioNTech Seek Approval for Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

Share this
Pfizer and BioNTech Seek Approval for Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

Pfizer and BioNTech Seek Approval for Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age

Shots:

  • The companies reported positive results from a P-II/III study evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the COVID-19 vaccine in healthy children through 5-11 years of age
  • In a sub analysis of 30 sera, the study demonstrated a 36-fold increase in SARS-CoV-2 Omicron variant and wild-type strain neutralizing titers following a booster dose of vaccine compared to two doses
  • In the study of 140 children, booster dosed increases neutralizing Abs by 6-fold against the SARS-CoV-2 wild-type strain in this age group. The companies plan to submit EUA to the US FDA in the coming days with additional submissions to other regulatory agencies worldwide to follow

Ref: Pfizer | Image: Pfizer

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions